Buprenorphine Market Modeling Methodology
INDIVIOR monitors sales data using prescription counts and unit quantities. In order to most accurately to track the opioid dependence market, we convert the unit quantities into the base MG components by multiplying the unit quantity by the dose strength of the product. This affords us the ability to analyze the business in a consolidated way, and removes the effects of dose mix and dosing paradigms. There are large differences in the quantities requested in each prescription because of variations in dose and duration. Because the market now offers many dosage strengths, counting units also does not give as clear a view of the market.
Therefore the most common method that INDIVIOR employs to maintain this consistency across time and product mix is to equalize the MG’s of buprenorphine across competitive entries. For example, ZUBSOLV® (buprenorphine and naloxone) sublingual tablet (CIII) launched with a 1.4mg and 5.7mg dose, claiming in vivo blood levels comparable to the 2mg and 8mg Suboxone Film. For comparison purposes, we convert the 1.4mg ZUBSOLV® tablet to 2mg of buprenorphine, and the 5.7mg ZUBSOLV® tablet to 8mg of buprenorphine. This allows market size consistency, patient dosing accuracy and market share equivalency across products and time.
We also include all generic forms of buprenorphine and buprenorphine/naloxone in our competitive market definition.
ZUBSOLV® is a licensed trademark of Orexo US, Inc.